Clinical Research Directory

Deflazacort Vs. Prednisolone in Acute-stage ABPA

Sponsor: Post Graduate Institute of Medical Education and Research, Chandigarh

Summary

Oral glucocorticoids are currently the treatment of choice for allergic bronchopulmonary aspergillosis (ABPA). They not only suppress the immune hyperfunction but are also anti-inflammatory. Unfortunately, numerous toxicities and adverse effects have been attributed to glucocorticoids related to both the average dose and cumulative duration of use. Deflazacort is a oxazoline steroid with demonstrated anti-inflammatory and immunosuppressant effects. The novel structural characteristic of deflazacort is associated with substantial lack of sodium-retaining activity, lower interference with carbohydrate metabolism and calcium metabolism in comparison with older glucocorticoids such as prednisolone. The investigators hypothesize that the occurrence of side-effects, primarily weight gain will be lower with deflazacort. In this study, the investigators will compare the safety and efficacy of deflazacort in the treatment of acute-stage ABPA complicating asthma.

Official title: A Randomized Controlled Trial of Deflazacort Vs. Prednisolone in Acute-stage Allergic Bronchopulmonary Aspergillosis

Key Details

Conditions

Interventions

Locations (1)